Compositions for affecting weight loss

Compositions for affecting weight loss

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 recep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HIGGIN MICHELLE S, MCKINNEY ANTHONY, MCCALL JOHN M, TOLLEFSON GARY
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator HIGGIN MICHELLE S
MCKINNEY ANTHONY
MCCALL JOHN M
TOLLEFSON GARY
description Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of alpha-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance alpha-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of alpha-MSH in the central nervous system.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2007117827A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2007117827A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2007117827A13</originalsourceid><addsrcrecordid>eNrjZFBzzs8tyC_OLMnMzytWSMsvUkhMS0tNLsnMS1coT81MzyhRyMkvLuZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGBuaGhuYWRuaOhsbEqQIALpcoxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Compositions for affecting weight loss</title><source>esp@cenet</source><creator>HIGGIN MICHELLE S ; MCKINNEY ANTHONY ; MCCALL JOHN M ; TOLLEFSON GARY</creator><creatorcontrib>HIGGIN MICHELLE S ; MCKINNEY ANTHONY ; MCCALL JOHN M ; TOLLEFSON GARY</creatorcontrib><description>Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of alpha-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance alpha-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of alpha-MSH in the central nervous system.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2007</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20070524&amp;DB=EPODOC&amp;CC=US&amp;NR=2007117827A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20070524&amp;DB=EPODOC&amp;CC=US&amp;NR=2007117827A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HIGGIN MICHELLE S</creatorcontrib><creatorcontrib>MCKINNEY ANTHONY</creatorcontrib><creatorcontrib>MCCALL JOHN M</creatorcontrib><creatorcontrib>TOLLEFSON GARY</creatorcontrib><title>Compositions for affecting weight loss</title><description>Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of alpha-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance alpha-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of alpha-MSH in the central nervous system.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2007</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFBzzs8tyC_OLMnMzytWSMsvUkhMS0tNLsnMS1coT81MzyhRyMkvLuZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGBuaGhuYWRuaOhsbEqQIALpcoxQ</recordid><startdate>20070524</startdate><enddate>20070524</enddate><creator>HIGGIN MICHELLE S</creator><creator>MCKINNEY ANTHONY</creator><creator>MCCALL JOHN M</creator><creator>TOLLEFSON GARY</creator><scope>EVB</scope></search><sort><creationdate>20070524</creationdate><title>Compositions for affecting weight loss</title><author>HIGGIN MICHELLE S ; MCKINNEY ANTHONY ; MCCALL JOHN M ; TOLLEFSON GARY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2007117827A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2007</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>HIGGIN MICHELLE S</creatorcontrib><creatorcontrib>MCKINNEY ANTHONY</creatorcontrib><creatorcontrib>MCCALL JOHN M</creatorcontrib><creatorcontrib>TOLLEFSON GARY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HIGGIN MICHELLE S</au><au>MCKINNEY ANTHONY</au><au>MCCALL JOHN M</au><au>TOLLEFSON GARY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Compositions for affecting weight loss</title><date>2007-05-24</date><risdate>2007</risdate><abstract>Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of alpha-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-beta-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance alpha-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of alpha-MSH in the central nervous system.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2007117827A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Compositions for affecting weight loss
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A51%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HIGGIN%20MICHELLE%20S&rft.date=2007-05-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2007117827A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true